Severe Asthma Cases Projected to Rise to 1.89 Million by 2033
Severe Asthma Cases Projected to Rise in the U.S. and Globally
The number of americans living with severe asthma is expected to climb in the coming decade, mirroring a global trend.
New data from GlobalData, a leading data and analytics company, forecasts a steady increase in severe asthma cases over the next ten years. In the United States, the 12-month diagnosed prevalent cases are projected to rise from 852,000 in 2023 to approximately 852,000 in 2033, representing an annual growth rate of 0.49%.
This upward trend is also reflected in lifetime diagnosed prevalent cases, which are expected to increase from 1.35 million in 2023 to 1.35 million in 2033, a growth rate of 0.30%.
The U.S. is projected to have the highest number of severe asthma cases among the eight major markets studied, which include France, Germany, Italy, Spain, the UK, Japan, and China. Japan is expected to have the fewest cases.
“The main reason for this expected increase is population growth and the relatively low mortality rate associated with asthma,” explains molly Moran, Senior Epidemiologist at GlobalData. ”Since severe asthma is often a lifelong disease, a growing population will inevitably lead to a larger number of individuals living with the condition.”
Understanding the Future Burden
Moran emphasizes that the future burden of severe asthma will be influenced by several factors, including overall asthma prevalence and the prevalence of risk factors like obesity and aging.
“Another crucial aspect to consider is the prevalence of inflammatory subtypes of severe asthma,” Moran adds. “Accurately characterizing severe asthma is critical, especially given the predicted increase in atopic or allergic asthma by 2033.”
This detailed understanding of the evolving landscape of severe asthma is essential for developing effective treatment strategies and public health initiatives to address the growing needs of patients.
Severe Asthma Cases on the Rise: A Looming Health Challenge
NewsDirectory3.com – Brace yourselves for a worrying trend: severe asthma cases are projected to climb significantly in the United States and globally over the next decade. This concerning rise mirrors a similar pattern observed in other major markets.
According to recent data released by GlobalData, a leading data and analytics company, the number of Americans living with severe asthma is expected to increase steadily. In the US, 12-month diagnosed prevalent cases are projected to rise from 852,000 in 2023 to approximately 852,000 in 2033, representing an annual growth rate of 0.49%. Lifetime diagnosed prevalent cases are also expected to increase during this period, going from 1.35 million in 2023 to 1.35 million in 2033, translating to a growth rate of 0.30%.
This alarming trend positions the US as the country with the highest projected number of severe asthma cases among eight major markets analyzed, including France, Germany, Italy, Spain, the UK, japan, and China.
“The primary driver behind this predicted increase is population growth and the relatively low mortality rate associated with asthma,” explains Molly Moran, Senior Epidemiologist at GlobalData. “Severe asthma is often a lifelong disease, so a growing population will naturally result in a larger number of individuals living with the condition.”
Moran emphasizes that several factors will contribute to the future burden of severe asthma. These include the overall prevalence of asthma, increasing rates of risk factors like obesity and aging, and the growing prevalence of inflammatory subtypes of severe asthma, notably atopic or allergic asthma.
“accurately characterizing severe asthma is crucial, particularly considering the projected rise in atopic asthma by 2033,” Moran adds.
This in-depth understanding of the evolving landscape of severe asthma is essential for healthcare professionals and policymakers alike. it allows for the development of effective treatment strategies and the implementation of targeted public health initiatives to address the growing needs of patients struggling with this debilitating condition.